Toggle Main Menu Toggle Search

Open Access padlockePrints

Browsing publications by Dr Elaine Willmore

Newcastle AuthorsTitleYearFull text
Erhan Aptullahoglu
Mohammed Howladar
Dr Jonathan Wallis
Dr Helen Marr
Professor Julie Irving
et al.		Targeting the MDM2-p53 Interaction with Siremadlin: A Promising Therapeutic Strategy for Treating TP53 Wild-Type Chronic Lymphocytic Leukemia2025
Hannah Smith
Dr Elaine Willmore
Dr Lisa Prendergast
Professor Nicola Curtin
ATR, CHK1 and WEE1 inhibitors cause homologous recombination repair deficiency to induce synthetic lethality with PARP inhibitors2024
Dr Celine Cano
Professor Jane Endicott
Dr Ian Hardcastle
Dr Claire Jennings
Suzanne Kyle
et al.		Discovery of ASTX295, a potent, next-generation small molecule antagonist of MDM2 with differentiated pharmacokinetic profile2024
Erhan Aptullahoglu
Dr Jonathan Wallis
Dr Helen Marr
Dr Elaine Willmore
Professor John Lunec
SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia2023
Dr Jill Hunter
Dr Elaine Willmore
Professor Julie Irving
Dr Stephany Veuger
Correction to: NF-kappa B mediates radio-sensitization by the PARP-1 inhibitor, AG-014699 (Oncogene, (2012), 31, 2, (251-264), 10.1038/onc.2011.229)2023
Dr Evan Mulligan
Dr Susan Tudhope
Dr Jill Hunter
Sarah Elliott
Dr Jonathan Wallis
et al.		Expression and Activity of the NF-κB Subunits in Chronic Lymphocytic Leukaemia: A Role for RelB and Non-Canonical Signalling2023
Dr Beth Adamson
Dr Nicholas Brittain
Dr Laura Walker
Ruaridh Duncan
Dr Sara Luzzi
et al.		The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer2023
Hannah Smith
Dr Elaine Willmore
Dr Asima Mukhopadhyay
Dr Yvette Drew
Professor Nicola Curtin
Differences in Durability of PARP Inhibition by Clinically Approved PARP Inhibitors: Implications for Combinations and Scheduling2022
Dr Carmela Ciardullo
Dr Katarzyna Szoltysek
Dr Peixun Zhou
Dr Elaine Willmore
Dr Amir Enshaei
et al.		Low BACH2 expression predicts adverse outcome in chronic lymphocytic leukaemia2022
Islam Al-Khawaldeh
Dr Christine Basmadjian
Dr Cinzia Bordoni
Dr Suzannah Harnor
Amy Heptinstall
et al.		An alkynylpyrimidine-based covalent inhibitor that targets a unique cysteine in NF-κB-inducing kinase (NIK)2021
Dr Timothy Barrow
Dr Elaine Willmore
Dr Gordon Strathdee
Dr Hyang-Min Byun
Analysis of retrotransposon subfamily DNA methylation reveals novel early epigenetic changes in chronic lymphocytic leukaemia2021
Dr Timothy Barrow
Dr Sirintra Nakjang
Kateryna Bilotkach
Dr Laura Woodhouse
Gesa Junge
et al.		Epigenome-wide analysis reveals functional modulators of drug sensitivity and post-treatment survival in chronic lymphocytic leukaemia2021
Dr Wei-Yu Lin
Dr Sarah Fordham
Dr Nicola Sunter
Dr Claire Elstob
Dr Thahira Rahman
et al.		Genome-wide association study identifies risk loci for progressive chronic lymphocytic leukemia2021
Dr Elaine Willmore
Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL2021
Dr Katarzyna Szoltysek
Dr Carmela Ciardullo
Dr Peixun Zhou
Dr Anna Walaszczyk
Dr Elaine Willmore
et al.		Dap kinase-related apoptosis-inducing protein kinase 2 (Drak2) is a key regulator and molecular marker in chronic lymphocytic leukemia2020
12345